New data confirm combination nivolumab and ipilimumab as the best treatment for unresectable malignant pleural mesothelioma (MPM).

The data come from the CheckMate 743 study (ClinicalTrials.gov Identifier: NCT02899299), which showed superior 3-year overall survival (OS) with nivo-ipi over standard chemotherapy and no new safety signals associated with nivo-ipi.

Advanced MPM has an extremely poor prognosis. Standard-of-care pemetrexed plus cisplatin chemotherapy produced a response rate of 41% and a median OS of 12.1 months in a phase 3 trial, but most patients experience no enduring benefit from treatment.

Get the full story at pulmonologyadvisor.com

Malignant Pleural Mesothelioma

Go To Source For Respiratory Therapy Coverage

RT delivers in-depth coverage of the clinical, regulatory, and technology landscape for respiratory therapy—and reaches more than 28,000 key decision-makers and influencers. As one of healthcare’s most important data companies, we facilitate the rapid adoption of medical devices and practice management tools into the industry. Go To Source For Respiratory Therapy Coverage

RT delivers in-depth coverage of the clinical, regulatory, and technology landscape for respiratory therapy—and reaches more than 28,000 key decision-makers and influencers. As one of healthcare’s most important data companies, we facilitate the rapid adoption of medical devices and practice management tools into the industry. Go To Source For Respiratory Therapy Coverage RT delivers in-depth coverage of the clinical, regulatory, and technology landscape for respiratory therapy—and reaches more than 28,000 key decision-makers and influencers. As one of healthcare’s most important data companies, we facilitate the rapid adoption of medical devices and practice management tools into the industry. Go To Source For Respiratory Therapy Coverage RT delivers in-depth coverage of the clinical, regulatory, and technology landscape for respiratory therapy—and reaches more than 28,000 key decision-makers and influencers. As one of healthcare’s most important data companies, we facilitate the rapid adoption of medical devices and practice management tools into the industry.